Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-10-12Clinical Trial Update: A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1]
Phase I study evaluating ganetespib with or without bortezomib in relapsed/refractory multiple myeloma has completed.
-
FDA approval · 2015-10-09FDA Approved: DOXORUBICIN HYDROCHLORIDE LIPOSOME — Supplemental Application (Baxter Healthcare Company)
FDA approved Baxter's supplemental NDA for doxorubicin hydrochloride liposome.
-
FDA label_change · 2015-10-08FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Sagent Pharmaceuticals)
FDA supplemental application for Zoledronic Acid submitted by Sagent Pharmaceuticals to modify the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2015-10-07Clinical Trial Update: Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04) [Phase 3]
This Phase 3 trial update reports completion of a study comparing Velcade-based induction regimens with dexamethasone and thalidomide versus…
-
CLINICAL_TRIALS trial_result · 2015-10-06Clinical Trial Update: NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma [Phase 2]
Updates from a Phase 2 trial evaluating NOX-A12 in combination with bortezomib and dexamethasone in relapsed multiple myeloma.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-10-06Clinical Trial Update: UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients [Phase 3]
Phase 3 study of Velcade, thalidomide, and dexamethasone with or without Adriamycin in relapsed/refractory multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2015-10-05Clinical Trial Update: Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma [NA]
This completed clinical trial evaluated lenalidomide plus azacitidine as adaptive immunotherapy before autologous stem cell transplantation …
-
CLINICAL_TRIALS trial_result · 2015-09-22Clinical Trial Update: UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy [Phase 3]
Phase 3 clinical trial update in multiple myeloma evaluating anti-angiogenesis with thalidomide plus post-transplant consolidation chemother…
-
FDA approval · 2015-09-21FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr. Reddy's Laboratories Limited)
The FDA approved a supplemental application for zoledronic acid from Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2015-09-17Clinical Trial Update: Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure [Phase 2]
Phase 2 study evaluating induction therapy with Velcade (bortezomib) and dexamethasone in previously untreated multiple myeloma patients wit…
-
CLINICAL_TRIALS trial_result · 2015-09-11Clinical Trial Update: A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma [Phase 3]
A Phase 3 trial compares thalidomide plus dexamethasone against dexamethasone alone in previously untreated multiple myeloma; the study stat…
-
CLINICAL_TRIALS trial_result · 2015-09-10Clinical Trial Update: UARK 2009-09 Myeloma Cure Project: Prospective Trial of Indefinite Revlimid Maintenance Versus Observation for Currently Event-Free Patients With Multiple Myeloma [Phase 3]
Phase 3 trial evaluating indefinite lenalidomide maintenance versus observation in currently event-free patients with multiple myeloma. Resu…
-
CLINICAL_TRIALS research · 2015-09-04Clinical Trial Update: Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Expanded-access single-patient program for the monoclonal antibody elotuzumab in a relapsed/refractory multiple myeloma patient (R-A); the p…
-
CLINICAL_TRIALS trial_result · 2015-09-02Clinical Trial Update: A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma [Phase 1, Phase 2]
Phase 1/2 dose-escalation study evaluating a triplet of lenalidomide, dexamethasone, and cyclophosphamide in patients with relapsed or refra…
-
CLINICAL_TRIALS trial_result · 2015-08-28Clinical Trial Update: Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma [Phase 1]
Phase 1 trial evaluating weekly oral ixazomib in adults with relapsed/refractory multiple myeloma completed with posted results.
-
CLINICAL_TRIALS trial_result · 2015-08-27Clinical Trial Update: Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) [Phase 1]
A completed Phase 1 safety study of ridaforolimus (MK-8669) in patients with advanced, refractory or recurrent malignancies, including lymph…
-
CLINICAL_TRIALS trial_result · 2015-08-27Clinical Trial Update: Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) [Phase 1]
Phase 1 safety study of AP23573 (deforolimus) in patients with advanced, refractory, or recurrent malignancies has completed, including lymp…
-
CLINICAL_TRIALS trial_result · 2015-08-19Clinical Trial Update: AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma [Phase 2]
Phase 2 trial of selumetinib (AZD6244) in patients with recurrent or refractory multiple myeloma has completed, with results posted in 2015.
-
CLINICAL_TRIALS withdrawal · 2015-08-19Clinical Trial Update: Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy [Phase 2]
A Phase 2 clinical trial evaluating monoclonal antibody therapy or biological therapy in patients with chronic lymphocytic leukemia or multi…
-
CLINICAL_TRIALS research · 2015-08-18Clinical Trial Update: Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China [Phase 1, Phase 2]
Clinical trial comparing subcutaneous versus intravenous administration of bortezomib in multiple myeloma patients in China across Phase 1 a…
-
CLINICAL_TRIALS trial_result · 2015-08-13Clinical Trial Update: Therapeutic Research in Multiple Myeloma
This clinical trial update reports the completion of a therapeutic research study for multiple myeloma sponsored by the University of Arkans…
-
CLINICAL_TRIALS trial_result · 2015-08-04Clinical Trial Update: A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma [Phase 3]
A phase 3 trial comparing carfilzomib to best supportive care in relapsed and refractory multiple myeloma has completed and posted results i…
-
FDA approval · 2015-08-04FDA Approved: MOZOBIL — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA approves a supplemental application for MOZOBIL (plerixafor) from Sanofi-Aventis U.S. LLC. The action updates the product's labeling and…
-
CLINICAL_TRIALS trial_result · 2015-08-04Clinical Trial Update: Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating Plerixafor plus G-CSF for mobilization and collection of peripheral hematopoietic stem cells in Japanese p…
-
CLINICAL_TRIALS trial_result · 2015-08-04Clinical Trial Update: A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating CNTO 328 plus bortezomib versus bortezomib alone in relapsed or refractory multiple myeloma; results posted after c…